Nanoencapsulation and characterization of Albizia chinensis isolated antioxidant quercitrin on PLA nanoparticles

Kumari, Avnesh; Yadav, Sudesh Kumar; Pakade, Yogesh B.; Kumar, Vineet; Singh, Bikram; Chaudhary, Anil; Yadav, Subhash Chandra

doi:10.1016/j.colsurfb.2010.08.046

Cited by 106 publications

(46 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…199,200 Furthermore, quercetin encapsulated with polyd,l-lactide nanoparticles with a size of approximately 130 nm produced using a solvent evaporation method enhances retention time to 96 hours. 55,201 These studies confirmed that nanosizing quercetin using various delivery techniques enhances its protective role against various neurological disorder animal models through its antioxidative effects.…”

Section: Nanoquercetinsupporting

confidence: 60%

Recent trends in the development of nanophytobioactive compounds and delivery systems for their possible role in reducing oxidative stress in Parkinson’s disease models

Ganesan¹,

Ko²,

Kim³

et al. 2015

IJN

View full text Add to dashboard Cite

Oxidative stress plays a very critical role in neurodegenerative diseases, such as Parkinson’s disease (PD), which is the second most common neurodegenerative disease among elderly people worldwide. Increasing evidence has suggested that phytobioactive compounds show enhanced benefits in cell and animal models of PD. Curcumin, resveratrol, ginsenosides, quercetin, and catechin are phyto-derived bioactive compounds with important roles in the prevention and treatment of PD. However, in vivo studies suggest that their concentrations are very low to cross blood–brain barrier thereby it limits bioavailability, stability, and dissolution at target sites in the brain. To overcome these problems, nanophytomedicine with the controlled size of 1–100 nm is used to maximize efficiency in the treatment of PD. Nanosizing of phytobioactive compounds enhances the permeability into the brain with maximized efficiency and stability. Several nanodelivery techniques, including solid lipid nanoparticles, nanostructured lipid carriers, nanoliposomes, and nanoniosomes can be used for controlled delivery of nanobioactive compounds to brain. Nanocompounds, such as ginsenosides (19.9 nm) synthesized using a nanoemulsion technique, showed enhanced bioavailability in the rat brain. Here, we discuss the most recent trends and applications in PD, including 1) the role of phytobioactive compounds in reducing oxidative stress and their bioavailability; 2) the role of nanotechnology in reducing oxidative stress during PD; 3) nanodelivery systems; and 4) various nanophytobioactive compounds and their role in PD.

show abstract

Section: Nanoquercetinsupporting

confidence: 60%

Recent trends in the development of nanophytobioactive compounds and delivery systems for their possible role in reducing oxidative stress in Parkinson’s disease models

Ganesan¹,

Ko²,

Kim³

et al. 2015

IJN

View full text Add to dashboard Cite

show abstract

“…The in vitro release kinetics of quercitrin under physiological condition reveals initial burst release followed by sustained release. These properties of quercitrin nanomedicine provide a new potential for the use of such less useful highly active antioxidant molecule towards the development of better therapeutic for intestinal anti-inflammatory effect and nutraceutical compounds [128] .…”

Section: Recent Advances Of Bioenhancersmentioning

confidence: 99%

Bioavailability enhancers of herbal origin: An overview

Kesarwani

Gupta

2013

Asian Pacific Journal of Tropical Biomedicine

362

197

View full text Add to dashboard Cite

“…16,[23][24][25][26][27] In addition, the drug-loading capacities of the optimized PPNMCs prepared here were mid value compared with that of other nanosized PLA particles reported earlier to range from 0.14% to 8%. 23,[25][26][27] These changes in entrapment efficiency and drug-loading capacity might be due to the different type, amount, and solubility properties of the agents used, as well as the different preparation methods used and aims of the experiments. In our study, PPNMCs were planned and produced, and enabled good sustained release of pyridostigmine.…”

Section: Validation Of Model Optimizationmentioning

confidence: 83%

Nanosized sustained-release pyridostigmine bromide microcapsules: process optimization and evaluation of characteristics

Tan¹,

Jiang²,

Xu³

et al. 2013

IJN

View full text Add to dashboard Cite

Background: Pyridostigmine bromide (3-[[(dimethylamino)-carbonyl]oxy]-1-methylpyridinium bromide), a reversible inhibitor of cholinesterase, is given orally in tablet form, and a treatment schedule of multiple daily doses is recommended for adult patients. Nanotechnology was used in this study to develop an alternative sustained-release delivery system for pyridostigmine, a synthetic drug with high solubility and poor oral bioavailability, hence a Class III drug according to the Biopharmaceutics Classification System. Novel nanosized pyridostigmine-poly(lactic acid) microcapsules (PPNMCs) were expected to have a longer duration of action than free pyridostigmine and previously reported sustained-release formulations of pyridostigmine. Methods: The PPNMCs were prepared using a double emulsion-solvent evaporation method to achieve sustained-release characteristics for pyridostigmine. The preparation process for the PPNMCs was optimized by single-factor experiments. The size distribution, zeta potential, and sustained-release behavior were evaluated in different types of release medium. Results: The optimal volume ratio of inner phase to external phase, poly(lactic acid) concentration, polyvinyl alcohol concentration, and amount of pyridostigmine were 1:10, 6%, 3% and 40 mg, respectively. The negatively charged PPNMCs had an average particle size of 937.9 nm. Compared with free pyridostigmine, PPNMCs showed an initial burst release and a subsequent very slow release in vitro. The release profiles for the PPNMCs in four different types of dissolution medium were fitted to the Ritger-Peppas and Weibull models. The similarity between pairs of dissolution profiles for the PPNMCs in different types of medium was statistically significant, and the difference between the release curves for PPNMCs and free pyridostigmine was also statistically significant. Conclusion: PPNMCs prepared by the optimized protocol described here were in the nanometer range and had good uniformity, with significantly slower pyridostigmine release than from free pyridostigmine. This novel sustained-release delivery nanosystem for pyridostigmine might alleviate the need to identify new acetylcholinesterase inhibitors.

show abstract

Nanoencapsulation and characterization of Albizia chinensis isolated antioxidant quercitrin on PLA nanoparticles

Cited by 106 publications

References 55 publications

Recent trends in the development of nanophytobioactive compounds and delivery systems for their possible role in reducing oxidative stress in Parkinson’s disease models

Recent trends in the development of nanophytobioactive compounds and delivery systems for their possible role in reducing oxidative stress in Parkinson’s disease models

Bioavailability enhancers of herbal origin: An overview

Nanosized sustained-release pyridostigmine bromide microcapsules: process optimization and evaluation of characteristics

Contact Info

Product

Resources

About

Nanoencapsulation and characterization of Albizia chinensis isolated antioxidant quercitrin on PLA nanoparticles

Cited by 106 publications

References 55 publications

Recent trends in the development of nanophytobioactive compounds and delivery systems for their possible role in reducing oxidative stress in Parkinson&rsquo;s disease models

Recent trends in the development of nanophytobioactive compounds and delivery systems for their possible role in reducing oxidative stress in Parkinson&rsquo;s disease models

Bioavailability enhancers of herbal origin: An overview

Nanosized sustained-release pyridostigmine bromide microcapsules: process optimization and evaluation of characteristics

Contact Info

Product

Resources

About

Recent trends in the development of nanophytobioactive compounds and delivery systems for their possible role in reducing oxidative stress in Parkinson’s disease models

Recent trends in the development of nanophytobioactive compounds and delivery systems for their possible role in reducing oxidative stress in Parkinson’s disease models